Antioxidative and Anti-Inflammatory Protective Effects of β-Caryophyllene against Amikacin-Induced Nephrotoxicity in Rat by Regulating the Nrf2/AMPK/AKT and NF-κB/TGF-β/KIM-1 Molecular Pathways

Rajab, Bodour S.; Albukhari, Talat A.; Khan, Anmar A.; Refaat, Bassem; Almehmadi, Samah J.; Nasreldin, Nani; Elshopakey, Gehad E.; El-Boshy, Mohamed

doi:https://doi.org/10.1155/2022/4212331

Oxidative Medicine and Cellular Longevity

On this page

Abstract Introduction Materials and Methods Results Discussion Data Availability Ethical Approval Conflicts of Interest Supplementary Materials References Copyright Related Articles

Research Article | Open Access

Volume 2022 | Article ID 4212331 | https://doi.org/10.1155/2022/4212331

Antioxidative and Anti-Inflammatory Protective Effects of β-Caryophyllene against Amikacin-Induced Nephrotoxicity in Rat by Regulating the Nrf2/AMPK/AKT and NF-κB/TGF-β/KIM-1 Molecular Pathways

Bodour S. Rajab,¹Talat A. Albukhari,²Anmar A. Khan,¹Bassem Refaat,¹Samah J. Almehmadi,¹Nani Nasreldin,³Gehad E. Elshopakey,⁴and Mohamed El-Boshy⁴

Academic Editor: Imtaiyaz Hassan

Received09 Apr 2022

Accepted04 Aug 2022

Published26 Aug 2022

Abstract

Herein, the molecular pathogenic pathways implicated in renal injury triggered by amikacin (AK), together with the alleviating actions of β-caryophyllene (BCP), were investigated. Adult male Wistar rats () were disseminated to the four following groups (/group): normal group, positive control animals (PC) that received AK intraperitoneal injections for 14 days (500 mg/kg/day), and rats that received AK simultaneously with small (200 mg/kg/day) and high doses (400 mg/kg/day) of BCP. The PC renal tissues revealed abnormal histology alongside increased apoptosis and significantly elevated serum creatinine and urea with marked proteinuria and oliguria relative to the normal rats. Moreover, renal tissues from the PC animals also showed substantial upregulations in NF-κB/TGF-β/KIM-1, whilst Nrf2/AMPK/AKT/PCNA declined, at the gene and protein levels in comparison to the normal rats. Additionally, the levels of markers of oxidative stress (MDA/H₂O₂/protein adducts) and inflammation (TNF-α/IL-1β/IL-6/IL-18/TLR/HSP25) were substantially higher in the PC renal specimens, whereas the antioxidants (GSH/GPx/SOD1/CAT) and interleukin-10 decreased, relative to the NC group. Both BCP protocols improved the biochemical markers of renal functions, alleviated renal histopathology and apoptosis, and decreased NF-κB/TGF-β/KIM-1 alongside the concentrations of oxidative stress and proinflammatory markers, whilst promoting Nrf2/AMPK/AKT/IL-10/PCNA and the targeted antioxidants. However, the improving effects in the high-dose regimen were markedly stronger than those observed in animals treated with low dose of BCP. In conclusion, the present report is the first to connect NF-κB/TGF-β/KIM-1 proinflammatory and Nrf2/AMPK/AKT antioxidative stress pathways with the pathogenesis of AK-induced nephrotoxicity. Additionally, the current report is the first to disclose alleviating activities for BCP against AK-triggered nephrotoxicity by modulating multiple antioxidative stress with anti-inflammatory molecular pathways.

1. Introduction

Amikacin (AK) is an aminoglycoside antibiotic frequently utilized for treating infections and neonatal renal abscess caused by gram-negative bacteria [1–4]. Renal tubular cells excrete the drug in urine without metabolism, and nephrotoxicity could occur by excess accumulation of AK in the renal cortex [5]. Suggested mechanisms for AK-induced renal injury include mitochondrial membrane damage and lysosomal dysfunction that subsequently intensify the production of free radicals, thus predisposing to cellular oxidative stress [3, 4]. Although the nephrotoxic effects of AK are dependent on dose and duration of treatment and could vary between individuals, acute renal failure is the most common complication [1, 5].

Although the molecular pathways involved in AK-induced nephrotoxicity are currently unclear, several experimental reports have revealed that AK triggers renal injury by oxidative stress and proinflammatory processes [6–8]. In this respect, many studies have proclaimed that AK accrues in renal tissues, which promotes mitochondrial dysfunction together with enhanced production of free radicals and declines in antioxidant molecules in renal tissues [7, 9]. Persistent oxidative stress subsequently triggers inflammation of renal tissues by upregulating nuclear factor-kappa B (NF-κB), Toll-like receptor (TLR), tumor necrosis factor- (TNF-) α, heat shock protein (HSP)25, interleukin- (IL-) 1, IL-6, and transforming growth factor- (TGF-) β [10–12]. Chronic oxidative stress and inflammation then incite renal cell damage, promote cell apoptosis, and increase the specific maker of renal tubular damage, kidney injury molecule-1 (KIM-1) [10–12]. In contrast, nuclear factor erythroid 2-related factor 2 (Nrf2) is a vital antioxidant and anti-inflammatory molecule, which is stimulated by protein kinase B (AKT) and mitogen-activated protein kinase (AMPK) [13–15]. Nonetheless, reports related to the roles of NF-κB/TGF-β/KIM-1, as well as Nrf2/AKT/AMPK in AK-induced renal injury, are lacking.

Spontaneous recovery from AK-induced renal dysfunction is improbable; also, there is no standard medication against this common complication [16]. Therefore, many experimental studies have suggested that natural antioxidant and anti-inflammatory products could provide an alternative prophylactic and/or therapeutic approaches against AK-induced nephropathy [4, 6, 17, 18]. Under this theme, β-caryophyllene (BCP) is a volatile ingredient of numerous plants that is mostly applied for food seasoning [19]. Despite that BCP showed effective antioxidative and anti-inflammatory nephroprotective activities [15, 20, 21], none of the prior studies explored its possible ameliorating actions against AK-induced renal impairment.

Hence, the current report was performed to study the functions of NF-κB/TGF-β/KIM-1 with Nrf2/AKT/AMPK pathways in the pathomechanisms of AK-induced renal dysfunction. Additionally, the present study also measured the potential nephroprotective activities of BCP against AK-induced renal injury. A better understanding about the roles of Nrf2/AKT/AMPK and NF-κB/TGF-β/KIM-1 molecular pathways in renal impairment associated with AK, as well as the potential effects of BCP on their expression in renal tissues, could provide a better prophylactic strategy against nephrotoxicity induced by aminoglycoside antibiotics.

2. Materials and Methods

2.1. Study Design and Prophylactic Protocols

Thirty-two male adult (12 weeks of age) Wistar rats (180-200 g/each) were maintained in a controlled environment ( with 12 h light/dark cycle) with normal chow and unrestricted access to water. The rats were divided after acclimatization to four equal groups, as follows ( rats/group): normal controls (NC), positive controls (PC) that were injected with amikacin only, and the last groups which concurrently received amikacin with either low (200 mg/kg; LD group) or high (400 mg/kg; HD group) oral BCP (Sigma-Aldrich Chemical Co.; MO, USA) doses. The normal group was injected intraperitoneally with normal saline, whilst freshly prepared intraperitoneal amikacin injections (500 mg/kg; AMIKACIN®; EIPICO Pharmaceuticals Co.; 10^th of Ramadan City, Egypt) alone or together with low or high oral BCP doses were given once daily to the assigned animals for 14 successive days, as described earlier [11, 15, 22]. Ethical approval was granted by the Ethics Board at Umm Al-Qura University, KSA (AMSEC 17/06-12-21).

2.2. Types of Samples

Following collection of 24 h urine samples (24 h-U) by housing each rat in a metabolic cage (Braintree Scientific Inc., MA, USA), euthanasia was done by cervical dislocation on the fifteenth day, as described earlier [23]. Venous blood was collected, and obtained serum was stored till used. Following excision of kidneys, a piece was used for histopathology. Renal total protein was collected by homogenizing a tissue specimen in a radioimmunoprecipitation assay buffer. Protease inhibitors were then added to inhibit protein degradation. The concentrations of total protein were quantified by a bicinchoninic acid assay (Thermo Fisher Scientific; CA, USA). Each sample was then diluted (1000 μg/mL) by deionized water. RNA extraction and cDNA production were achieved by commercial kits (Thermo Fisher Scientific).

2.3. Biochemical Markers of Renal Functions

Systemic concentrations of creatinine (Cr), urea, total protein, and albumin with 24 h-U Cr and total protein concentrations were measured on a fully automated Cobas analyzer (Wiener Lab, Switzerland) using a commercially available kit according to the instructor’s pamphlet.

The 24 h urine flow and Cr clearance (Cr-Cl) were calculated, as reported earlier [24]:

2.4. Relative Gene Expression

The expression of the targeted genes was measured on a real-time apparatus (QuantStudio™ 3 Real-Time PCR) and by processing each renal cDNA sample in triplicate wells/gene followed by 40 PCR amplification cycles, as described earlier [25]. Each well contained 1 μL of cDNA (25 ng), 2 μL of nuclease-free water, SYBR Green master mix (5 μL), and a mixture of 5 pmol forward and reverse primers (2 μL; Supplementary Table 1). Two negative controls were used as follows: cDNA samples were substituted with nuclease-free water, whilst the other control was replaced with extracted total RNA without reverse transcription. GAPDH gene was used for normalization, and the 2^-∆∆Ct approach was employed to measure the expression of the genes of interest relative to the GAPDH gene.

2.5. Immunohistochemistry (IHC)

Protein expression of NF-κB p50, TGF-β1, AMPKα, AKT1, and Nrf2 was detected with rabbit primary polyclonal IgG antibodies, whereas primary goat polyclonal IgG antibodies were utilized for detecting KIM-1, in renal tissues (Thermo Fisher Scientific). Following overnight incubation of renal tissue sections with the primary antibodies (1 : 200 concentration; 4°C), the slides were washed and incubated for 30 minutes with ImmPRESS® HRP-conjugated Horse Anti-Rabbit or Anti-Goat IgG Plus Polymer Peroxidase Kits (Vector Laboratories Inc.; CA, USA). Rabbit or goat IgG isotype antibodies (Santa Cruz Biotechnology Inc.; TX, USA) were used in replacement of the primary antibodies to control for nonspecific binding. The slides were then observed with a brightfield microscope (Leica Microsystems, Wetzlar, Germany). Images were then acquired from 10 nonintersecting areas/section. The IHC scores were determined by ImageJ software (https://imagej.nih.gov/ij/), as reported earlier [26].

2.6. Terminal Deoxynucleotidyl Transferase-dUTP Nick End Labelling (TUNEL) Technique

Detection of DNA damage/apoptosis in renal tissues was done by a Click-iT™ TUNEL Alexa Fluor™ 488 Imaging Assay (Thermo Fisher Scientific). Next, dual expression of proliferating cell nuclear antigen (PCNA) with apoptotic bodies was done by adding anti-PCNA mouse monoclonal IgG antibodies (1 : 100 dilution) for 3 h. Following washing, Alexa Fluor™ 555-conjugated secondary donkey antimouse IgG antibodies were used. The sections were counterstained with DAPI (Thermo Fisher Scientific). All slides were then examined by a fluorescent microscope (Leica Microsystems). Percentages of apoptosis were determined by calculating the apoptotic/necrotic cells in 15 nonintersecting areas/slide, as reported earlier [27].

2.7. Enzyme-Linked Immunosorbent Assay (ELISA)

The concentrations of TNF-α, IL-1β, IL-6, IL-10, IL-18, HSP25, and TLR4 in renal tissue homogenates were measured by ELISA (Cloud-Clone Corp.; TX, USA). Similarly, renal tissue concentrations of malondialdehyde (MDA), protein carbonyl groups, hydrogen peroxide, glutathione (GSH), superoxide dismutase-1 (SOD1), catalase (CAT), and glutathione peroxidase-1 (GPx1) were also measured by ELISA kits (Cell Biolabs, Inc.; CA, USA). The samples were processed by an automated ELISA machine (Poweam Medical Systems Co., Ltd; China).

2.8. Statistical Analysis

SPSS software version 25 was used, and data normality and homogeneity were determined by the Kolmogorov and Smirnov test and the Levene test, correspondingly. According to variance equality, one-way ANOVA test with Tukey’s HSD or Games-Howell post hoc tests were applied for comparing between the groups. value < 0.05 indicated statistical significance.

3. Results

3.1. Serum and Urine Markers of Renal Function

Levels of 24 h urine total protein in addition to Cr and urea in serum were significantly higher, whilst serum total protein and albumin together with 24 h urine volume and flow, Cr levels, and Cr clearance declined markedly, in the PC rats relative to the normal animals (Table 1; ). Both BCP treatment protocols showed significant reductions in serum creatinine and urea with concurrent increases in systemic total protein and albumin levels in addition to 24 h urine amounts and Cr clearance, compared with the PC animals (). Nevertheless, the improvements were significantly more pronounced with the high-dose regimen compared to the LD regimen (Table 1; ). Moreover, all the tested serum and urine markers of renal function in the HD group were similar to the NC animals, except for urine concentrations of total protein that were substantially higher in the prior group ().

3.2. Morphology of Renal Tissues

The NC renal tissues stained with H&E showed normal histological characteristics, and the percentages of apoptotic bodies were scarce, whilst renal expression of PCNA protein was abundant (Figure 1(a)). In contrast, the PC animals revealed substantial glomerular and tubular damage depicted by glomerular basal membrane detachment, cupping of Bowman’s capsule, marked protrusion of tubular cells with lumen widening, and interstitial necrosis with marked leukocytic infiltration (Figure 1(a)). Moreover, the mRNA and protein expression of PCNA decreased ( for both), whereas apoptosis index increased (), drastically in renal specimens from the positive controls compared to normal rats (Figures 1(b)–1(d)). Treatments with both BCP doses in amikacin-intoxicated animals attenuated renal histopathology, upregulated PCNA, and lowered the numbers of apoptotic bodies, significantly relative to the positive control animals (Figure 1; ). Whilst the HD group displayed substantially enhanced histology and markedly higher PCNA protein with lower percentages of apoptotic cells relative to rats treated with a low dose of BCP (P <0.01), all the markers remained significantly abnormal compared to normal renal specimens (Figure 1; for all).

(a) Renal histology and apoptosis markers

(b) Relative expression () of PCNA gene in renal tissue

(c) Arbitrary scores () of PCNA relative protein expression in renal tissue

(d) Apoptosis index () in renal tissue by TUNEL technique

3.3. Renal Expression of Pathogenic and Protective Molecules

NF-κB p50, TGF-β1, and KIM-1 (Figure 2) in addition to Nrf2, AMPK-α, and AKT1 (Figure 3) were detected at the gene and protein levels in renal tissues from normal rats. Whilst the mRNAs and proteins of NF-κB p50, TGF-β1, and KIM-1 increased significantly (Figure 2; for all), those of Nrf2, AMPK-α, and AKT1 decreased markedly (Figure 3; for all), in the PC renal samples than in the negative control group. Despite that the low and high BCP doses modulated the expression of the tested molecules relative to the positive control animals, the effects were markedly more manifested in the rats that received a high BCP dose (Figures 2 and 3; for all markers). Nevertheless, the mRNAs and proteins of NF-κB p50, TGF-β1, and KIM-1 were substantially higher, whereas those of Nrf2, AMPK-α, and AKT1 were substantially lower, in the HD animals relative to the NC renal tissues.

(a) Protein expression by IHC

(b) Gene expression and IHC arbitrary scores

(a) Protein expression by IHC

(b) Gene expression and IHC arbitrary scores

3.4. Renal Gene Expression and Concentrations of Inflammatory and Oxidative Stress Molecules

TNF-α, IL-1β, IL-6, IL-18, HSP25, and TLR4 mRNAs increased significantly in the renal specimens from the positive controls relative to the normal rats (Figure 3; ). Treatment with both doses of BCP significantly reduced the mRNAs of TNF-α, IL-1β, IL-6, IL-18, HSP25, and TLR4 genes in renal tissues in comparison to the PC rats (Figure 3). The LD group showed drastically higher gene expression of TNF-α, IL-1β, IL-6, IL-18, HSP25, and TLR4 in comparison to the negative control animals (), whereas the HD and NC groups showed a similar expression profile (Figure 4).

Concurrently, renal concentrations of TNF-α, IL-1β, IL-6, IL-18, HSP25, TLR4, MDA, H₂O₂, and protein carbonyl groups increased, whilst IL-10, GSH, SOD1, GPx1, and CAT decreased, substantially in the PC animals compared to the normal group (Table 2). The concentrations of inflammatory and prooxidative stress markers in renal tissues decreased, whereas those of IL-10 and antioxidants increased, markedly with both BCP regimens relative to the PC animals. Nonetheless, the anti-inflammatory and antioxidant molecules were considerably higher in the high-dose than the low-dose regimen (Table 2). Although the concentrations of TNF-α, IL-1β, IL-6, TLR4, IL-10, SOD1, GPx1, and CAT were comparable in the HD and NC renal specimens, IL-18, HSP25, MDA, H₂O₂, and protein carbonyl groups were markedly higher and concurred with significantly lower GSH and CAT in the animals that received a high dose of BCP (Table 2).

4. Discussion

Herein, we explored the molecular pathogenic pathways that could contribute to AK-induced nephropathy. Moreover, we investigated the alleviating actions of BCP against renal oxidative stress and inflammation associated with AK nephrotoxicity. Our results demonstrated significant increases in serum Cr and urea that coincided with recessions in serum concentrations of total protein and albumin together with low urine volume, proteinuria, and reduced urine Cr clearance in the PC rats compared to the normal animals. Renal samples from the PC groups also showed substantial increases in MDA, H₂O₂, and protein carbonyl groups alongside declines in renal GSH, SOD1, GPx1, and CAT. Additionally, the proinflammatory markers (TNF-α, IL-1β, IL-6, IL-18, HSP25, & TLR4) increased, whilst IL-10 decreased, at the gene and protein levels in the PC renal specimens in comparison to the normal rats.

Aminoglycoside antibiotics, including amikacin, are associated with several adverse events, and patients could develop acute renal failure with elevated serum creatinine and urea alongside reductions in urine output and urine creatinine clearance [1, 5]. At the tissue level, AK-induced renal injury is linked with marked glomerular damage, tubular necrosis, interstitial inflammation, and increased leucocytic infiltration [9, 28]. Suggested mechanisms for AK-induced nephropathy include mitochondrial damage with increased ROS production together with declines in renal antioxidant molecules (e.g., GSH/SOD/GPx1/CAT), thus promoting the formation of free radicals, lipid peroxides, and protein adducts that subsequently provoke renal cell damage [3, 4, 7, 9]. Moreover, renal oxidative stress is believed to trigger inflammation by upregulating several proinflammatory cytokines (e.g., IL-1β, IL-6, and TNF-α, HSP25, and TLR4) with simultaneous inhibition of IL-10, which is a robust anti-inflammatory molecule [10–12]. Our results agree with many prior studies that advocated major roles for oxidative stress and inflammation in the pathomechanisms of renal injury caused by AK [3, 4, 7, 9–12].

Although NF-κB, TGF-β, and Nrf2 are chief modulators of redox biology and inflammatory responses in the kidney, little is known regarding their contributions to AK-induced nephrotoxicity. In this regard, several renal pathologies are linked with substantial increases in NF-κB [29, 30] and TGF-β1 [31, 32] that consequently stimulate numerous proinflammatory cytokines. Moreover, coactivation of renal NF-κB and TGF-β pathways aggravates tissue inflammation and initiates apoptosis [33–35]. Furthermore, both molecules also increased substantially in rat renal tissues with gentamicin treatment, which is another aminoglycoside antibiotic linked with renal injury [36]. On the other hand, Nrf2 is a key molecule that regulates cellular antioxidant pathways, and the protein decreases significantly in renal tissues with a variety of diseases induced by oxidative stress [37, 38]. Additionally, curcumin attenuated gentamycin-induced renal injury by increasing the production of Nrf2 [39]. Similarly, the AMPK/AKT pathway contributes to the regulation of cellular antioxidant and anti-inflammatory networks, and the activation of this pathway alleviated renal injury induced by oxidative stress and proinflammatory stimulants [40–42].

As far as we are aware, this study is the first to reveal drastic elevations in NF-κB, TGF-β1, and KIM-1 gene and protein expression, whereas the mRNAs and proteins of AMPK-α, AKT1, and Nrf2 decreased, in the renal samples from the PC animals relative to normal rats. Furthermore, the percentages of apoptotic cells increased, whilst the mRNA and protein of PCNA declined, significantly in the positive control renal specimens compared to the NC animals. Therefore, we hypothesize that AK-induced renal cell injury might encompass upregulations of NF-κB and TGF-β1 with concurrent downregulations in AMPK-α, AKT1, and Nrf2 that trigger cell death via oxidative stress and inflammation with simultaneous inhibition of the survival protein, PCNA [36–40]. Moreover, we suggest that KIM-1 could be utilized to monitor tubular damage during treatment with aminoglycoside antibiotics [15, 43, 44]. However, further work is mandatory to study the connections between the different molecular mechanisms involved in AK-induced nephropathy to corroborate our suggestions.

Prevention and clinical management of AK-induced nephrotoxicity mainly involves using alternative antibiotics, increasing intervals between doses, and inhibition of aminoglycoside reuptake by tubular cells to minimize renal damage [16, 45, 46]. On the other hand, numerous experimental studies have shown renoprotective actions for several antioxidant and anti-inflammatory nutraceutical products against aminoglycoside-induced nephrotoxicity [4, 11, 39, 42]. In the present study, the addition of low or high doses of BCP with AK reduced serum and urine biochemical markers of renal injury, protected against renal histological damage, decreased renal apoptosis index, and increased PCNA gene and protein expression compared to the positive control rats. Additionally, both BCP regimens reduced the renal concentrations of oxidative stress molecules and diminished several proinflammatory cytokines with concomitant increases in the concentrations of antioxidants and IL-10 compared to the renal samples from the PC rats. However, the ameliorating activities were significantly more apparent with the high BCP dose relative to the low-dose group.

BCP is a common natural component of many plants that has shown potent antioxidant and anti-inflammatory actions [47–49]. In this regard, BCP treatment alleviated renal impairment induced by hyperoxaluria in murine by reducing NF-κB and KIM-1, enhancing renal antioxidant mechanisms, and promoting cell survival [50]. Likewise, BCP reduced the concentrations of NF-κB with many inflammatory markers, whilst increasing several Nrf2-dependent antioxidant molecules, hence alleviating the complications associated with high glucose on mesangial cells [51]. Similar effects were also shown after using BCP for attenuating sulfasalazine-induced renal damage that involved reductions in NF-κB and TGF-β alongside increased Nrf2, AMPK, and AKT concentrations [15]. BCP therapy also reduced lipopolysaccharide-induced acute lung injury in mice by decreasing a variety of inflammatory cytokines, including TGF-β [52]. Likewise, Ullah et al. documented anti-inflammatory actions for BCP by suppressing TLR activity and upregulating the AMPK pathway in the nervous system [53]. BCP also mitigated cerebral injury in rat, as well as inhibited fat deposition in human liver cells, by stimulating the AMPK/AKT pathway [54, 55]. Furthermore, several previous reports have shown that treatment with different doses of BCP for short and long periods of administration was safe and not associated with toxic effects in healthy animals [56, 57].

Our observations correlate with many prior studies and suggest that BCP could be used as a safe prophylactic nephroprotective substance against nephropathy associated with AK treatment by downregulating NF-κB and TGF-β1 and simultaneously enhancing antioxidative mechanisms by upregulating Nrf2-regulated molecules in renal tissues [15, 50–52, 54, 55]. However, additional experiments are still required to measure the therapeutic benefit of BCP following inducing renal impairment by aminoglycoside antibiotics.

In conclusion, the current study is the first to demonstrate that renal oxidative stress and inflammation following AK treatment could involve aberrant renal expression of NF-κB, TGF-β1, Nrf2, AMPK, and AKT molecular networks. Although low- and high-dose protocols of BCP alleviated AK-induced renal impairment by enhancing antioxidative stress and anti-inflammatory activities, the best ameliorative outcomes were detected with the latter regimen. However, farther studies are essential to measure the therapeutic benefits of BCP against nephrotoxicity and ototoxicity induced by aminoglycoside antibiotics.

Data Availability

The data used to support the findings of this study may be released upon application to the corresponding author, Mohamed El-Boshy, who can be contacted through the following email: [email protected].

Ethical Approval

Ethical approval was obtained from the Committee for the Care and Use of Laboratory Animals at Umm Al-Qura University, KSA (AMSEC 17/06-12-21).

Conflicts of Interest

The authors declare that there is no conflict of interest.

Supplementary Materials

Supplementary Table 1: the sequences of PCR primers used for the detection of rat GAPDH, Nfkb1, TGF-β1, KIM-1 (Havcr1), AMPK-α, Nrf2 (Nfe2l2), AKT1, PCNA, TNF-α, IL-1β, IL-6, IL-18, HSP25 (HSBP1), and TLR4 mRNAs in renal samples including the corresponding gene accession numbers and amplicon sizes. (Supplementary Materials)

References

S. M. Illamola, C. M. Sherwin, and J. G. C. van Hasselt, “Clinical pharmacokinetics of amikacin in pediatric patients: a comprehensive review of population pharmacokinetic analyses,” Clinical Pharmacokinetics, vol. 57, no. 10, pp. 1217–1228, 2018.
View at: Publisher Site | Google Scholar
T. Yamada, S. Fujii, A. Shigemi, and Y. Takesue, “A meta-analysis of the target trough concentration of gentamicin and amikacin for reducing the risk of nephrotoxicity,” Journal of Infection and Chemotherapy, vol. 27, no. 2, pp. 256–261, 2021.
View at: Publisher Site | Google Scholar
A. R. Da Silveira, É. V. F. Rosa, M. H. M. Sari et al., “Therapeutic potential of beta-caryophyllene against aflatoxin B1-induced liver toxicity: biochemical and molecular insights in rats,” Chemico-Biological Interactions, vol. 348, article 109635, 2021.
View at: Publisher Site | Google Scholar
A. Selim, M. M. Khalaf, A. M. Gad, and O. M. Abd El-Raouf, “Evaluation of the possible nephroprotective effects of vitamin E and rosuvastatin in amikacin-induced renal injury in rats,” Journal of Biochemical and Molecular Toxicology, vol. 31, no. 11, p. e21957, 2017.
View at: Publisher Site | Google Scholar
A. Jenkins, A. H. Thomson, N. M. Brown et al., “Amikacin use and therapeutic drug monitoring in adults: do dose regimens and drug exposures affect either outcome or adverse events? A systematic review,” Journal of Antimicrobial Chemotherapy, vol. 71, no. 10, pp. 2754–2759, 2016.
View at: Publisher Site | Google Scholar
H. Parlakpinar, M. K. Ozer, M. Ucar et al., “Protective effects of caffeic acid phenethyl ester (CAPE) on amikacin-induced nephrotoxicity in rats,” Cell Biochemistry and Function, vol. 24, no. 4, pp. 363–367, 2006.
View at: Publisher Site | Google Scholar
G. Bulut, Y. Basbugan, E. Ari et al., “Paricalcitol may improve oxidative DNA damage on experimental amikacin-induced nephrotoxicity model,” Renal Failure, vol. 38, no. 5, pp. 751–758, 2016.
View at: Publisher Site | Google Scholar
E. Lecain, B. Omri, F. Behar-Cohen, P. Tran Ba Huy, and P. Crisanti, “The role of PKCzeta in amikacin-induced apoptosis in the cochlea: prevention by aspirin,” Apoptosis, vol. 12, no. 2, pp. 333–342, 2007.
View at: Publisher Site | Google Scholar
A. Kara, H. Cetin, F. Oktem, I. Metin Ciris, I. Altuntas, and S. Kaya, “Amikacin induced renal damage and the role of the antioxidants on neonatal rats,” Renal Failure, vol. 38, no. 5, pp. 671–677, 2016.
View at: Publisher Site | Google Scholar
K. A. Wargo and J. D. Edwards, “Aminoglycoside-induced nephrotoxicity,” Journal of Pharmacy Practice, vol. 27, no. 6, pp. 573–577, 2014.
View at: Publisher Site | Google Scholar
N. Madbouly, A. Azmy, A. Salama, and A. El-Amir, “The nephroprotective properties of taurine-amikacin treatment in rats are mediated through HSP25 and TLR-4 regulation,” The Journal of Antibiotics, vol. 74, no. 9, pp. 580–592, 2021.
View at: Publisher Site | Google Scholar
K. Sridharan, M. Al Jufairi, O. Al Segai et al., “Biomarkers in neonates receiving potential nephrotoxic drugs,” European Review for Medical and Pharmacological Sciences, vol. 25, no. 22, pp. 7078–7088, 2021.
View at: Publisher Site | Google Scholar
Y. Nie, Z. Wang, G. Chai et al., “Dehydrocostus lactone suppresses LPS-induced acute lung injury and macrophage activation through NF-κB signaling pathway mediated by p38 MAPK and Akt,” Molecules, vol. 24, no. 8, p. 1510, 2019.
View at: Publisher Site | Google Scholar
M. Tanaka, Y. Kishimoto, M. Sasaki et al., “Terminalia bellirica (Gaertn.) Roxb. extract and gallic acid attenuate LPS-induced inflammation and oxidative stress via MAPK/NF-κB and Akt/AMPK/Nrf2 pathways,” Oxidative Medicine And Cellular Longevity, vol. 2018, Article ID 9364364, 2018.
View at: Publisher Site | Google Scholar
B. Refaat and M. El-Boshy, “Protective antioxidative and anti-inflammatory actions of β-caryophyllene against sulfasalazine-induced nephrotoxicity in rat,” Experimental Biology and Medicine, vol. 247, no. 8, pp. 691–699, 2022.
View at: Publisher Site | Google Scholar
F. Paquette, A. Bernier-Jean, V. Brunette et al., “Acute kidney injury and renal recovery with the use of aminoglycosides: a large retrospective study,” Nephron, vol. 131, no. 3, pp. 153–160, 2015.
View at: Publisher Site | Google Scholar
M. K. Ozer, H. Asci, M. Oncu et al., “Effects of pentoxifylline on amikacin-induced nephrotoxicity in rats,” Renal Failure, vol. 31, no. 2, pp. 134–139, 2009.
View at: Publisher Site | Google Scholar
M. K. Ozer, S. Bilgic, I. Armagan, and M. Savran, “Thymoquinone protection from amikacin induced renal injury in rats,” Biotechnic & Histochemistry: Official Publication Of The Biological Stain Commission, vol. 95, no. 2, pp. 129–136, 2020.
View at: Publisher Site | Google Scholar
G. E. Batiha, L. M. Alkazmi, L. G. Wasef, A. M. Beshbishy, E. H. Nadwa, and E. K. Rashwan, “Syzygium aromaticum L. (Myrtaceae): traditional uses, bioactive chemical constituents, pharmacological and toxicological activities,” Biomolecules, vol. 10, no. 2, 2021.
View at: Google Scholar
L. F. S. Gushiken, F. P. Beserra, M. F. Hussni et al., “Beta-caryophyllene as an antioxidant, anti-inflammatory and re-epithelialization activities in a rat skin wound excision model,” Oxidative Medicine and Cellular Longevity, vol. 2022, Article ID 9004014, 2022.
View at: Publisher Site | Google Scholar
H. Sadeghi, M. Mansourian, E. Panahi Kokhdan et al., “Antioxidant and protective effect of Stachys pilifera Benth against nephrotoxicity induced by cisplatin in rats,” Journal of Food Biochemistry, vol. 44, no. 5, article e13190, 2020.
View at: Publisher Site | Google Scholar
K. Chan, K. R. Ledesma, W. Wang, and V. H. Tam, “Characterization of amikacin drug exposure and nephrotoxicity in an animal model,” Antimicrobial Agents and Chemotherapy, vol. 64, no. 9, 2020.
View at: Publisher Site | Google Scholar
M. El-Boshy, B. Refaat, R. A. Almaimani et al., “Vitamin D₃ and calcium cosupplementation alleviates cadmium hepatotoxicity in the rat: enhanced antioxidative and anti-inflammatory actions by remodeling cellular calcium pathways,” Journal of Biochemical and Molecular Toxicology, vol. 34, no. 3, article e22440, 2020.
View at: Publisher Site | Google Scholar
M. El-Boshy, A. Alsaegh, A. H. Qasem et al., “Enhanced renoprotective actions of Paricalcitol and omega-3 fatty acids co-therapy against diabetic nephropathy in rat,” Journal of Advanced Research, vol. 38, pp. 119–129, 2022.
View at: Publisher Site | Google Scholar
B. Refaat, A. H. Abdelghany, J. Ahmad et al., “Vitamin D3 enhances the effects of omega-3 oils against metabolic dysfunction-associated fatty liver disease in rat,” BioFactors, vol. 48, no. 2, pp. 498–513, 2021.
View at: Publisher Site | Google Scholar
B. Refaat, A. H. Abdelghany, J. Ahmad et al., “Vitamin D(3) enhances the effects of omega-3 oils against metabolic dysfunction-associated fatty liver disease in rat,” BioFactors, vol. 48, no. 2, pp. 498–513, 2021.
View at: Publisher Site | Google Scholar
B. Refaat, A. H. Abdelghany, M. A. BaSalamah, M. El-Boshy, J. Ahmad, and S. Idris, “Acute and chronic iron overloading differentially modulates the expression of cellular iron-homeostatic molecules in normal rat kidney,” The Journal Of Histochemistry And Cytochemistry: Official Journal Of The Histochemistry Society, vol. 66, no. 11, pp. 825–839, 2018.
View at: Publisher Site | Google Scholar
E. E. Doğan, R. Erkoç, İ. Ekinci et al., “Protective effect of dexpanthenol against nephrotoxic effect of amikacin: an experimental study,” Biomedicine & Pharmacotherapy, vol. 89, pp. 1409–1414, 2017.
View at: Publisher Site | Google Scholar
H. Zhang and S. C. Sun, “NF-κB in inflammation and renal diseases,” Cell & Bioscience, vol. 5, no. 1, p. 63, 2015.
View at: Publisher Site | Google Scholar
N. Song, F. Thaiss, and L. Guo, “NFκB and kidney injury,” Frontiers in Immunology, vol. 10, p. 815, 2019.
View at: Publisher Site | Google Scholar
L. S. Gewin, “Transforming growth factor-β in the acute kidney injury to chronic kidney disease transition,” Nephron, vol. 143, no. 3, pp. 154–157, 2019.
View at: Publisher Site | Google Scholar
M. El-Boshy, M. A. BaSalamah, J. Ahmad et al., “Vitamin D protects against oxidative stress, inflammation and hepatorenal damage induced by acute paracetamol toxicity in rat,” Free Radical Biology and Medicine, vol. 141, pp. 310–321, 2019.
View at: Publisher Site | Google Scholar
Y. Y. Gu, X. S. Liu, X. R. Huang, X. Q. Yu, and H. Y. Lan, “Diverse role of TGF-β in kidney disease,” Frontiers in Cell and Developmental Biology, vol. 8, p. 123, 2020.
View at: Publisher Site | Google Scholar
L. S. Zhang, J. Li, and L. Jia-Ping, “Rhein-8-O-β-D-glucopyranoside inhibited high glucose-induced apoptosis of human mesangial cells by regulating the lincRNA ANRIL/let-7a/TGF-β1/Smad signaling pathway,” Experimental and Therapeutic Medicine, vol. 19, no. 4, pp. 2871–2878, 2020.
View at: Publisher Site | Google Scholar
A. Soltani Hekmat, A. Chenari, H. Alipanah, and K. Javanmardi, “Protective effect of alamandine on doxorubicin-induced nephrotoxicity in rats,” BMC Pharmacology & Toxicology, vol. 22, no. 1, p. 31, 2021.
View at: Publisher Site | Google Scholar
K. Jaikumkao, A. Pongchaidecha, L. O. Thongnak et al., “Amelioration of renal inflammation, endoplasmic reticulum stress and apoptosis underlies the protective effect of low dosage of atorvastatin in gentamicin-induced nephrotoxicity,” PLoS One, vol. 11, no. 10, article e0164528, 2016.
View at: Publisher Site | Google Scholar
K. Mousavi, H. Niknahad, H. Li et al., “The activation of nuclear factor-E2-related factor 2 (Nrf2)/heme oxygenase-1 (HO-1) signaling blunts cholestasis-induced liver and kidney injury,” Toxicology Research, vol. 10, no. 4, pp. 911–927, 2021.
View at: Publisher Site | Google Scholar
C. Yu, H. Dong, Q. Wang et al., “Danshensu attenuates cisplatin-induced nephrotoxicity through activation of Nrf2 pathway and inhibition of NF-κB,” Biomedicine & Pharmacotherapy, vol. 142, article 111995, 2021.
View at: Publisher Site | Google Scholar
D. Uzun-Goren and Y. H. Uz, “Protective effect of curcumin against gentamicin-induced nephrotoxicity mediated by p38 MAPK, nuclear factor-kappa B, nuclear factor erythroid 2-related factor 2,” Iranian Journal of Kidney Diseases, vol. 16, no. 2, pp. 96–107, 2022.
View at: Google Scholar
W. Lieberthal, M. Tang, M. Abate, M. Lusco, and J. S. Levine, “AMPK-mediated activation of Akt protects renal tubular cells from stress-induced apoptosis in vitro and ameliorates ischemic AKI in vivo,” American Journal of Physiology Renal Physiology, vol. 317, no. 1, pp. F1–f11, 2019.
View at: Publisher Site | Google Scholar
C. Rodríguez, C. Contreras, J. Sáenz-Medina et al., “Activation of the AMP-related kinase (AMPK) induces renal vasodilatation and downregulates Nox-derived reactive oxygen species (ROS) generation,” Redox Biology, vol. 34, article 101575, 2020.
View at: Publisher Site | Google Scholar
R. Hasan, S. Lasker, A. Hasan et al., “Canagliflozin ameliorates renal oxidative stress and inflammation by stimulating AMPK-Akt-eNOS pathway in the isoprenaline-induced oxidative stress model,” Scientific Reports, vol. 10, no. 1, p. 14659, 2020.
View at: Publisher Site | Google Scholar
W. S. Waring and A. Moonie, “Earlier recognition of nephrotoxicity using novel biomarkers of acute kidney injury,” Clinical toxicology (Philadelphia, Pa), vol. 49, no. 8, pp. 720–728, 2011.
View at: Publisher Site | Google Scholar
T. H. Quang, M. P. Nguyet, D. P. Thao et al., “Evaluation of urinary neutrophil gelatinase associated lipocalin and kidney injury molecule-1 as diagnostic markers for early nephropathy in patients with type 2 diabetes mellitus,” Diabetes, Metabolic Syndrome And Obesity: Targets And Therapy, vol. 13, pp. 2199–2207, 2020.
View at: Publisher Site | Google Scholar
M. Mahi-Birjand, S. Yaghoubi, M. Abdollahpour-Alitappeh et al., “Protective effects of pharmacological agents against aminoglycoside-induced nephrotoxicity: a systematic review,” Expert Opinion on Drug Safety, vol. 19, no. 2, pp. 167–186, 2020.
View at: Publisher Site | Google Scholar
X. Fu, P. Wan, P. Li et al., “Mechanism and prevention of ototoxicity induced by aminoglycosides,” Frontiers In Cellular Neuroscience, vol. 15, article 692762, 2021.
View at: Publisher Site | Google Scholar
H. M. Hashiesh, M. F. N. Meeran, C. Sharma, B. Sadek, J. A. Kaabi, and S. K. Ojha, “Therapeutic potential of β-caryophyllene: a dietary cannabinoid in diabetes and associated complications,” Nutrients, vol. 12, no. 10, p. 2963, 2020.
View at: Publisher Site | Google Scholar
R. Scandiffio, F. Geddo, E. Cottone et al., “Protective effects of (E)-β-caryophyllene (BCP) in chronic inflammation,” Nutrients, vol. 12, no. 11, p. 3273, 2020.
View at: Publisher Site | Google Scholar
H. M. Hashiesh, C. Sharma, S. N. Goyal et al., “A focused review on CB2 receptor-selective pharmacological properties and therapeutic potential of β-caryophyllene, a dietary cannabinoid,” Biomedicine & Pharmacotherapy, vol. 140, article 111639, 2021.
View at: Publisher Site | Google Scholar
X. Xu and J. Yan, “β-Caryophyllene may attenuate hyperoxaluria-induced kidney dysfunction in rats by regulating stress marker KIM-1/MCP-1 and NF-κB signaling pathway,” Journal of Biochemical And Molecular Toxicology, vol. 35, no. 11, article e22891, 2021.
View at: Publisher Site | Google Scholar
H. Li, D. Wang, Y. Chen, and M. Yang, “β-Caryophyllene inhibits high glucose-induced oxidative stress, inflammation and extracellular matrix accumulation in mesangial cells,” International Immunopharmacology, vol. 84, article 106556, 2020.
View at: Publisher Site | Google Scholar
Y. Zhang, H. Zhang, Y. Li, M. Wang, and F. Qian, “β-Caryophyllene attenuates lipopolysaccharide-induced acute lung injury via inhibition of the MAPK signalling pathway,” The Journal of Pharmacy And Pharmacology, vol. 73, no. 10, pp. 1319–1329, 2021.
View at: Publisher Site | Google Scholar
H. Ullah, A. Di Minno, C. Santarcangelo, H. Khan, and M. Daglia, “Improvement of oxidative stress and mitochondrial dysfunction by β-caryophyllene: a focus on the nervous system,” Antioxidants (Basel, Switzerland), vol. 10, no. 4, p. 546, 2021.
View at: Publisher Site | Google Scholar
Q. Zhang, R. An, X. Tian et al., “β-Caryophyllene pretreatment alleviates focal cerebral ischemia-reperfusion injury by activating PI3K/Akt signaling pathway,” Neurochemical Research, vol. 42, no. 5, pp. 1459–1469, 2017.
View at: Publisher Site | Google Scholar
R. Kamikubo, K. Kai, K. Tsuji-Naito, and M. Akagawa, “β-Caryophyllene attenuates palmitate-induced lipid accumulation through AMPK signaling by activating CB2 receptor in human HepG2 hepatocytes,” Molecular Nutrition & Food Research, vol. 60, no. 10, pp. 2228–2242, 2016.
View at: Publisher Site | Google Scholar
D. Schmitt, R. Levy, and B. Carroll, “Toxicological evaluation of β-caryophyllene oil: subchronic toxicity in rats,” International Journal Of Toxicology, vol. 35, no. 5, pp. 558–567, 2016.
View at: Publisher Site | Google Scholar
G. Oliveira, K. C. Machado, K. C. Machado, A. da Silva, C. M. Feitosa, and F. R. de Castro Almeida, “Non-clinical toxicity of β-caryophyllene, a dietary cannabinoid: absence of adverse effects in female Swiss mice,” Regulatory Toxicology And Pharmacology: Rtp, vol. 92, pp. 338–346, 2018.
View at: Publisher Site | Google Scholar

Copyright

Copyright © 2022 Bodour S. Rajab et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

PDF Download Citation

Download other formats

Order printed copies

Views

586

Downloads

409

Citations